EG ECCOGENE
Live / Applied — First extension granted (statement of use) (as of 23 Dec 2025)
What this means for you
Not registered yet, but its 10 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98794060
- Mark type
- Design + words
- Filed
- 10 Oct 2024
- Published for opposition
- 20 May 2025
- Attorney of record
- Wade Savoy
Goods and services
- Class 005 — Pharmaceuticals: (Based on Intent to Use) Pharmaceutical preparations for the treatment of obesity, cardiometabolic conditions, and inflammatory conditions
- Class 042 — Scientific and technological services: (Based on Use in Commerce) Pharmaceutical research and development; Research and development in the field of pharmaceuticals, obesity, cardiometabolic conditions, inflammatory conditions, small molecule therapeutics, and GLP-1 receptor agonists
Owner
- Eccogene, Inc., Cambridge, MA, US
- Eccogene, Inc., Cambridge, MA, US
Prosecution history
- 24 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
- 23 Dec 2025 — SOU EXTENSION 1 GRANTED
- 23 Dec 2025 — SOU EXTENSION 1 FILED
- 23 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 May 2025 — PUBLISHED FOR OPPOSITION
- 14 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Apr 2025 — EXAMINER'S AMENDMENT ENTERED
- 16 Apr 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 16 Apr 2025 — EXAMINERS AMENDMENT E-MAILED
- 16 Apr 2025 — EXAMINERS AMENDMENT -WRITTEN
- 14 Apr 2025 — ASSIGNED TO EXAMINER